Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1Adenoma, Islet Cell 1

Interventions

Dexamethasone 124Lenalidomide 72daratumumab 71Bortezomib 58pomalidomide 47carfilzomib 42Cyclophosphamide 39Calcium Dobesilate 36Specimen Handling 31Biopsy 29Magnetic Resonance Spectroscopy 26belantamab mafodotin 22isatuximab 21fludarabine 20iberdomide 18talquetamab 17Melphalan 15dexamethasone acetate 14dexamethasone 21-phosphate 14auricularum 14fludarabine phosphate 13elotuzumab 12selinexor 10tocilizumab 9X-Rays 8Nivolumab 8trametinib 7Whole-Body Irradiation 7Sirolimus 7Mycophenolic Acid 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × incomplete Freund's adjuvant × 90 days × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡